Kanamycin is an aminoglycoside antibiotic agent used in the treatment of various infections caused by susceptible bacteria. Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections.
- Mechanism
- Curator reviewed
Aminoglycosides like kanamycin "irreversibly" bind to specific 30S-subunit proteins and 16S rRNA. Specifically Kanamycin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes.
- Primary indication
- For treatment of infections where one or more of the following are the known or suspected pathogens: E. coli, Proteus species (both indole-positive and indole-negative), E. aerogenes, K. pneumoniae, S. marcescens, and Acinetobacter species.Curator reviewed · 6 structured indications
- Formula / weight
- C18H36N4O11 · 484.4986 g/mol (avg)
- First approval
- United States, 2003
- Also known as
- Kanamycin A
- Code names
- 8063-07-8
Resolves to
SBUJHOSQTJFQJX-NOAMYHISSA-NSMILESNC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Kanamycin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account